메뉴 건너뛰기




Volumn 56, Issue 5, 2005, Pages 481-486

Biweekly oxaliplatin combined with oral capecitabine (OXXEL regimen) as first-line treatment of metastatic colorectal cancer patients: A Southern Italy Cooperative Oncology Group phase II study

Author keywords

Biweekly treatment; Capecitabine; Metastatic colorectal cancer; Oxaliplatin; OXXEL regimen

Indexed keywords

CAPECITABINE; OXALIPLATIN;

EID: 27644511668     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-005-1003-6     Document Type: Article
Times cited : (10)

References (19)
  • 1
    • 0036533777 scopus 로고    scopus 로고
    • Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer
    • Borner MM, Dietrich D, Stupp R et al (2002) Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer. J Clin Oncol 20:1759-1766
    • (2002) J Clin Oncol , vol.20 , pp. 1759-1766
    • Borner, M.M.1    Dietrich, D.2    Stupp, R.3
  • 2
    • 2942638081 scopus 로고    scopus 로고
    • XELOX (capecitabine plus oxaliplatin): Active first-line therapy for patients with metastatic colorectal cancer
    • Cassidy J, Tabernero J, Twelves C, et al (2004) XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Onc 22:2084-2091
    • (2004) J Clin Onc , vol.22 , pp. 2084-2091
    • Cassidy, J.1    Tabernero, J.2    Twelves, C.3
  • 3
    • 27644540140 scopus 로고    scopus 로고
    • Oxaliplatin (OXA) plus levo-folinic acid (1-FA) and 5-fluorouacil (FU) i.v. bolus (OXAFAFU) is more active than irinotecan (IRI) plus levo-folinic acid (1-FA) and 5-fluorouacil (FU) i.v. bolus (IR-IFAFU) in advanced colorectal carcinoma (ACC): Final results of the Southern Italy Cooperative Oncology Group (SICOG) trial 0103
    • abstract# 271PD
    • Comella P, Massidda B, Filippelli G, et al (2004) Oxaliplatin (OXA) plus levo-folinic acid (1-FA) and 5-fluorouacil (FU) i.v. bolus (OXAFAFU) is more active than irinotecan (IRI) plus levo-folinic acid (1-FA) and 5-fluorouacil (FU) i.v. bolus (IR-IFAFU) in advanced colorectal carcinoma (ACC): Final results of the Southern Italy Cooperative Oncology Group (SICOG) trial 0103. Ann Oncol 15 (Supplement 3): iii72, abstract# 271PD
    • (2004) Ann Oncol , vol.15 , Issue.3 SUPPL.
    • Comella, P.1    Massidda, B.2    Filippelli, G.3
  • 5
    • 9744230871 scopus 로고    scopus 로고
    • OPTIMOX study: FOLFOX7/LV5FU2 compared to FOLFOX4 in patients with advanced colorectal cancer
    • abstract# 3525
    • De Gramont A, Cervantes A, André T et al (2004) OPTIMOX study: FOLFOX7/LV5FU2 compared to FOLFOX4 in patients with advanced colorectal cancer. Proc Am Soc Clin Oncol 251s, abstract# 3525
    • (2004) Proc Am Soc Clin Oncol
    • De Gramont, A.1    Cervantes, A.2    André, T.3
  • 6
    • 6444230253 scopus 로고    scopus 로고
    • A phase II study of Gefitinib in combination with FOLFOX-4 (IFOX) in patients with metastatic colorectal cancer
    • abstract# 3514
    • Fisher GA, Kuo T, Cho CD et al (2004) A phase II study of Gefitinib in combination with FOLFOX-4 (IFOX) in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 248s, abstract# 3514
    • (2004) Proc Am Soc Clin Oncol
    • Fisher, G.A.1    Kuo, T.2    Cho, C.D.3
  • 7
    • 1842569206 scopus 로고    scopus 로고
    • A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer
    • Goldberg RM, Sargent DJ, Morton RF et al (2004) A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23-30
    • (2004) J Clin Oncol , vol.22 , pp. 23-30
    • Goldberg, R.M.1    Sargent, D.J.2    Morton, R.F.3
  • 8
    • 2142730276 scopus 로고    scopus 로고
    • Capecitabine plus irinotecan (CAPIRI) vs capecitabine plus oxaliplatin (CAPOX) as first-line therapy of advanced colorectal cancer (ACRC): Updated results of a randomized phase II trial
    • abstract# 295
    • Grothey A, Jordan K, Kellner O et al (2003) Capecitabine plus irinotecan (CAPIRI) vs capecitabine plus oxaliplatin (CAPOX) as first-line therapy of advanced colorectal cancer (ACRC): updated results of a randomized phase II trial. Eur J Cancer S90, abstract# 295
    • (2003) Eur J Cancer
    • Grothey, A.1    Jordan, K.2    Kellner, O.3
  • 9
    • 0035871538 scopus 로고    scopus 로고
    • Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study
    • Hoff PM, Ansari R. Batisti G et al (2001) Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 19:2282-2292
    • (2001) J Clin Oncol , vol.19 , pp. 2282-2292
    • Hoff, P.M.1    Ansari, R.2    Batisti, G.3
  • 10
    • 33845382806 scopus 로고
    • Non-parametric estimation from incomplete observations
    • Kaplan EL, Meier P (1958) Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457-481
    • (1958) J Am Stat Assoc , vol.53 , pp. 457-481
    • Kaplan, E.L.1    Meier, P.2
  • 11
    • 0033636033 scopus 로고    scopus 로고
    • Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer
    • Oncology Multidisciplinary Research Group (GERCOR)
    • Maindrault-Gœbel F, de Gramont A, Louvet C et al (2000) Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR). Ann Oncol 11:1477-1483
    • (2000) Ann Oncol , vol.11 , pp. 1477-1483
    • Maindrault-Gœbel, F.1    De Gramont, A.2    Louvet, C.3
  • 12
    • 0035032625 scopus 로고    scopus 로고
    • High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7)
    • Maindrault-Gœbel F, de Gramont A, Louvet C et al (2001) High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7). Eur J Cancer 37:1000-1005
    • (2001) Eur J Cancer , vol.37 , pp. 1000-1005
    • Maindrault-Gœbel, F.1    De Gramont, A.2    Louvet, C.3
  • 14
    • 0037837645 scopus 로고    scopus 로고
    • Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer
    • Scheithauer WS, Kornek GV, Raderer M, et al (2003) Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 21:1307-1312
    • (2003) J Clin Oncol , vol.21 , pp. 1307-1312
    • Scheithauer, W.S.1    Kornek, G.V.2    Raderer, M.3
  • 15
    • 0024536437 scopus 로고
    • Optimal two stage design for phase II clinical trials
    • Simon R (1989) Optimal two stage design for phase II clinical trials. Contr Clin Trial 10:1-10
    • (1989) Contr Clin Trial , vol.10 , pp. 1-10
    • Simon, R.1
  • 16
    • 6444243519 scopus 로고    scopus 로고
    • An international phase II study of cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLOFOX-4) in the first-line treatment of patients with metastatic colorectal cancer (CRC) expressing Epidermal Growth Factor Receptor (EGFR): Preliminary results
    • abstract# 3512
    • Tabernero JM, Van Cutsem E, Sastre J et al (2004) An international phase II study of cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLOFOX-4) in the first-line treatment of patients with metastatic colorectal cancer (CRC) expressing Epidermal Growth Factor Receptor (EGFR): Preliminary results. Proc Am Soc Clin Oncol 248s, abstract# 3512
    • (2004) Proc Am Soc Clin Oncol
    • Tabernero, J.M.1    Van Cutsem, E.2    Sastre, J.3
  • 17
    • 0036176033 scopus 로고    scopus 로고
    • Capecitabine as first-line treatment in colorectal cancer: Pooled data from two large, phase III trials
    • Twelves C, on behalf of the Xeloda Colorectal Cancer Group (2002) Capecitabine as first-line treatment in colorectal cancer: pooled data from two large, phase III trials. Eur J Cancer 38:S15-S20
    • (2002) Eur J Cancer , vol.38
    • Twelves, C.1
  • 18
    • 0035503151 scopus 로고    scopus 로고
    • Oral capecitabine compared with intravenous 5-fluorouracil plus leucovorin (Mayo Clinic regimen) in patients with metastatic colorectal cancer: Results of a large phase III study
    • Van Cutsem E, Twelves C, Cassidy J et al (2001) Oral capecitabine compared with intravenous 5-fluorouracil plus leucovorin (Mayo Clinic regimen) in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 19:4097-4106
    • (2001) J Clin Oncol , vol.19 , pp. 4097-4106
    • Van Cutsem, E.1    Twelves, C.2    Cassidy, J.3
  • 19
    • 0141725528 scopus 로고    scopus 로고
    • Phase II study of capecitabine and oxaliplatin as first-line treatment in advanced colorectal cancer
    • Zeuli M, Nardoni C, Pino MS et al (2003) Phase II study of capecitabine and oxaliplatin as first-line treatment in advanced colorectal cancer. Ann Oncol 14:1378-1382
    • (2003) Ann Oncol , vol.14 , pp. 1378-1382
    • Zeuli, M.1    Nardoni, C.2    Pino, M.S.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.